Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors. - Barron's
1. VRTX stock dropped 15% after drug trial failure announcement. 2. VX-993 did not meet primary study endpoint, halting its advancement. 3. Company's quarterly earnings beat expectations but were overshadowed by news. 4. VX-993 was expected to enhance non-opioid pain treatment portfolio. 5. VRTX was the worst performer in the S&P 500 premarket trading.